Rational Design of Mitochondria-Targeted Antioxidants: From Molecular Determinants to Clinical Perspectives
Drugs and Drug Candidates · 20.01.2026 · 5 (1) · 9
DOI: 10.3390/ddc5010009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs and Drug Candidates, online erschienen am 20.01.2026. Verfasst von Beata Franczyk und 11 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Oxidative stress, caused by an imbalance between the production of reactive oxygen species and endogenous antioxidant capacity, is a key etiological factor in numerous pathologies, including neurodegenerative and cardiovascular diseases. The limited clinical efficacy of conventional antioxidants is primarily due to their insufficient accumulation within the mitochondria, the main site of intracellular ROS generation. This article reviews the design and application of Mitochondria-Targeted Antioxidants, which represent a major advance in precision medicine. The design of these compounds involves linking an antioxidant “payload” to a lipophilic cation, such as the triphenylphosphonium group. This positive charge leverages the negative electrochemical gradient across the inner mitochondrial membrane to drive the antioxidant into the organelle. This mechanism allows the drug to reach concentrations over 100 times higher than non-targeted alternatives. The discussion encompasses the structure-activity analysis of the carrier, the payload (e.g., quinone derivatives), and the linker, which determine optimal subcellular partitioning and scavenging efficiency. Preclinical data highlight the therapeutic potential of this approach, showing strong neuroprotection in models of Parkinson’s and Alzheimer’s diseases, as well as improved outcomes in cardiovascular and ocular health. By restoring redox balance specifically within the mitochondria, these targeted therapies offer a more effective way to treat chronic oxidative damage.
Zitieren
APA
Franczyk, B., Bojdo, K., Chłądzyński, J., Hossa, K., Krawiranda, K., Krupińska, N., Kustosik, N., Leszto, K., Lisińska, W., Wieczorek, A., Rysz, J., & Młynarska, E. (2026). Rational Design of Mitochondria-Targeted Antioxidants: From Molecular Determinants to Clinical Perspectives. Drugs and Drug Candidates, 5(1), 9. https://doi.org/10.3390/ddc5010009
Vancouver
Franczyk B, Bojdo K, Chłądzyński J, Hossa K, Krawiranda K, Krupińska N, et al. Rational Design of Mitochondria-Targeted Antioxidants: From Molecular Determinants to Clinical Perspectives. Drugs and Drug Candidates. 2026;5(1):9. doi:10.3390/ddc5010009
BibTeX
@article{Franczyk2026,
author = {Franczyk, Beata and Bojdo, Kinga and Chłądzyński, Jakub and Hossa, Katarzyna and Krawiranda, Katarzyna and Krupińska, Natalia and Kustosik, Natalia and Leszto, Klaudia and Lisińska, Wiktoria and Wieczorek, Anna and Rysz, Jacek and Młynarska, Ewelina},
title = {Rational Design of Mitochondria-Targeted Antioxidants: From Molecular Determinants to Clinical Perspectives},
journal = {Drugs and Drug Candidates},
year = {2026},
volume = {5},
number = {1},
pages = {9},
doi = {10.3390/ddc5010009}
}
EUVIMED